Chimeric Therapeutics Ltd. (AU:CHM) has released an update.
Chimeric Therapeutics Ltd., a leading Australian cell therapy company, has announced the resignation of CEO and Managing Director Jennifer Chow, effective May 24, 2024. Chow played a pivotal role in advancing the company’s cell therapy assets, growing the portfolio, and progressing clinical trials. The company has committed to unveiling changes to its executive team soon and continues to develop innovative cancer treatments, with multiple clinical programs underway.
For further insights into AU:CHM stock, check out TipRanks’ Stock Analysis page.
